Basic Information



GTO ID GTC3991
Trial ID NCT00805376
Disease Brain Glioma
Altered gene E1A|RGD
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment Ad5-Delta 24RGD|DNX-2401|tasadenoturev
PhasePhase1
Recruitment statusCompleted
TitlePhase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
Year2009
CountryUnited States
Company sponsorDNAtrix, Inc.
Other ID(s)ID01-310
Vector information
Vectoradenovirus
ConstructAd5-Delta 24RGD
Vector typetumor-selective, replication-competent oncolytic adenovirus
Transgene/Inserted geneRGD-motif, which was engineered into the fiber H-loop, enabling the virus to use αvβ3 or αvβ5 integrins to enter cells.
Regulatory elementRGD-motif
Viral genome modification24-base-pair deletion in the E1A gene

Clinical Result

Cohort 1
Administration route intratumoral injection
Pts 37
Age Adult, Older_Adult
References PMID: 29432077

Relationship Graph

Overview of Knowledge Graph